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Abstract: Primary aldosteronism is a common form of endocrine hypertension mainly caused by a unilat-
eral aldosterone-producing adenoma (APA) or bilateral adrenal hyperplasia (BAH). AT1R-Abs (autoanti-
bodies to the angiotensin II type 1 receptor) have been reported in patients with disorders associated with
hypertension. Our objective was to assess AT1R-Ab levels in patients with primary aldosteronism (APA,
n=40 and BAH, n=40) relative to patients with primary hypertension (n=40), preeclampsia (n=23),
and normotensive individuals (n=25). AT1R-Abs in whole sera were measured using 2 different ELISAs
which gave contrasting results. A functional cell-based assay was used to quantify activation of the AT1R
(angiotensin II type 1 receptor) using whole sera or affinity-purified antibodies in the absence or pres-
ence of losartan (a specific AT1R antagonist). Serum samples from all groups displayed different levels
of AT1R activation with different responses to losartan. Patients with BAH displayed higher losartan-
independent affinity-isolated agonistic AT1R-Ab levels compared with patients with APA (<0.01) and
with normotensive individuals (<0.0001). In patients with APA, BAH, and primary hypertension com-
bined, higher aldosterone-to-renin ratios and lower plasma renin concentrations were associated with
higher compared with lower agonistic AT1R-Ab levels. In patients with primary aldosteronism, higher
AT1R-Ab activity was associated with an increased likelihood of a diagnosis of BAH compared with APA
and with the presence of adrenal hyperplasia detected by computed tomography. Taken together, these
data suggest that agonistic AT1R-Abs may have a functional role in a subgroup of patients with primary
aldosteronism.
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Primary aldosteronism (PA) is a form of endocrine hy-pertension caused by the overproduction of aldosterone 
from one or both adrenal glands (unilateral or bilateral PA, 
respectively). Unilateral PA is predominantly caused by an 
aldosterone-producing adenoma (APA) and bilateral forms by 
bilateral adrenocortical hyperplasia (BAH).1 APA and BAH 
mainly arise sporadically, but uncommon familial forms have 
been described (familial hyperaldosteronism types I-IV).2,3 
Substantial progress has been made in understanding the path-
ophysiology of familial PA and sporadic APAs with the iden-
tification of germline mutations causing 4 familial forms of 
hyperaldosteronism4–9 and somatic mutations which drive al-
dosterone excess in 50% to 80% of APAs.2,10–12 These advances, 
however, have not been replicated in understanding the patho-
genesis of sporadic BAH. The bilateral nature of the disease 
led to the proposal of circulating factors, which could trigger 
bilateral chronic stimulation of the adrenal zona glomerulosa.
Graves disease is an established example of an autoimmune 
disease caused by agonistic autoantibodies which activate the 
TSHR (thyroid-stimulating hormone receptor) resulting in 
thyroid hormone production and thyroid cell proliferation.13–15 
In addition to agonistic antibodies, antagonistic and neutral 
autoantibodies to the TSHR have been described which either 
block TSH activity or have no apparent effect.15 Autoimmune 
responses to other G protein-coupled receptors have been re-
ported in several studies implicating a role for autoantibody 





-adrenergic receptors in several car-
diovascular disorders.16–25 Furthermore, multiple studies 
have reported the detection of AT1R-Abs (autoantibodies 
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to the angiotensin II type 1 receptor) in patients with pree-
clampsia.20,26 AT1R-Abs, which recognize the AFHYESQ 
peptide (position 165–171) in the second extracellular loop 
of the AT1R, have been implicated as autoantibody-mediated 
drivers of AT1R agonism. Specifically, ELISAs employing an 
immobilized synthetic AFHYESQ peptide are often used to 
assay AT1R-Ab levels.20,27 Using either ELISA or functional 
assays, AT1R-Abs have also been reported in patients with PA 
in whom AT1R-Ab levels are variously reported as higher in 
patients with APA than with BAH, higher in BAH compared 
with APA, or similar levels in both subtypes of PA.28–30 These 
studies have either used ELISA-based assays, which do not 
provide information on the agonistic effect of AT1R-Abs, or 
have included only small cohorts of patients with PA.
Our objective was to establish if functionally active AT1R-
Abs are present in a large cohort of 80 patients with PA (40 
patients with APA and 40 with BAH) in comparison with primary 
hypertension (PH, n=40), preeclampsia (n=23), and normoten-
sive individuals (NT, n=25) using 3 assays: 2 different ELISA-
based assays both using immobilized full-length AT1R and a 
highly sensitive cell-based AT1R activation functional assay.
Methods
The data that support the findings of this study are available from the 
corresponding author on reasonable request.
Patient Samples
For quantification of AT1R-Abs and AT1R activating activity, serum 
samples from 80 patients with PA (40 with APA and 40 with BAH), 
40 with PH, 23 women with preeclampsia, and 25 NT were used. PA 
was diagnosed in accordance with the Endocrine Society guideline.31 
Patients were screened for PA using the plasma aldosterone-to-direct 
renin concentration ratio, and diagnosis was confirmed by the intra-
venous saline load test according to local criteria.32 All patients with 
confirmed PA underwent computed tomography (CT) scanning and 
adrenal venous sampling. The cutoff selectivity index to determine 
success of catheterization was ≥2 and for the lateralization index to 
diagnose unilateral PA ≥4.32 PH was diagnosed in accordance with 
the European Society Hypertension/cardiology guidelines33 after rul-
ing out PA, pheochromocytoma and Cushing syndrome. Preeclampsia 
and Graves disease were diagnosed as described previously.34,35 Blood 
sampling for patients with PA and PH was performed at screening 
for secondary hypertension. Whenever possible, patients were under 
no treatment or before the beginning of an antihypertensive therapy. 
When necessary, blood pressure was controlled using the calcium 
channel blocker verapamil or the α-blocker doxazosin, alone or in 
combination, in accordance with the ES guideline.31 Blood samples 
from patients with Graves disease were withdrawn at the first med-
ical visit and from patients with preeclampsia in the third trimester. 
All participants gave written informed consent, and the protocol was 
approved by the local ethics committee.
AT1R Autoantibody Measurements
All AT1R-Abs were measured using 3 different assays. 2 commer-
cially available ELISA kits were used to quantify autoantibodies 
against the recombinant human full-length AT1R (ELISA-Creative 
Diagnostics and ELISA-CellTrend).36,37 The third assay was a cell-
based AT1R activation assay (Invitrogen Gene BLAzer beta-lacta-
mase reporter system) to measure agonistic AT1R activity in total 
serum and in affinity-isolated IgG fractions after preincubation for 
1 hour with vehicle or 100 µmol/L losartan. Immunoglobulins were 
affinity-isolated on protein A/G agarose from 1 mL patient serum, 
and 1/10 of the affinity-isolated IgGs was used in the functional assay. 
The isolation of IgGs on protein A/G agarose and their depletion from 
serum samples was confirmed by Western blotting using a horseradish 
peroxidase-conjugated goat anti-human antibody (Millipore, 1:50000 
dilution; Figure S1 in the online-only Data Supplement).
The cell-based AT1R activation assay employed AT1R-bla U2OS 
cells which stably express the AT1R linked at the C-terminus to 
the Gal4-VP16 transcription factor via a tobacco etch virus (TEV) 
protease cleavage site (E-X-X-Y-X-Q-G/S; Invitrogen). The U2OS 
cells also stably express TEV protease-tagged-β-arrestin/TEV and a 
β-lactamase reporter gene with Gal4-responsive upstream activator 
sequences. After AT1R activation, the TEV-protease-β-arrestin is re-
cruited to the AT1R receptor C-terminus and cleaves the TEV cleav-
age sequence releasing GAL4-VP16 which activates expression of 
the β-lactamase reporter gene. A Förster resonance energy transfer 
substrate comprising coumarin and fluorescein fluorophores was used 
to measure reporter gene activity (ThermoFisher, LiveBLAzer-FRET 
B/G substrate). In the absence of β-lactamase reporter gene expres-
sion, the Förster resonance energy transfer substrate is intact, couma-
rin excitation transfers fluorescence resonance energy to fluorescein 
resulting in emission of green fluorescence. When the substrate is 
cleaved, energy transfer is disrupted, and a blue fluorescence signal is 
emitted from coumarin excitation. Reporter activities, corresponding 
to AT1R activation, are given as response ratios which are the ratio 
of coumarin to fluorescein fluorescence signals (ratio of cleaved to 
uncleaved substrate) normalized for negative control wells (mock-
treated cells).
TSHR Activation Assay
Activity of affinity-isolated IgGs from serum of Graves disease 
patients was measured using a TSHR agonistic cell-based assay to 
determine if autoantibody functional activity was maintained after 
the IgG isolation procedure. The assay uses TSHR ACTOne cells, 
a HEK-293 CNG (human embryonic kidney-293 cyclic nucleotide-
gated) cell line with overexpression of recombinant human TSHR 
(MyBiosource). The modified CNG channel opens in response to 
elevated intracellular cAMP levels, and the resultant ion influx and 
membrane depolarization are measured with a fluorescent membrane 
potential dye. The assay measures intracellular cAMP levels as a re-
sponse ratio between TSHR ACTOne cells compared with the pa-
rental control cell line (HEK-293 CNG cells).
Adrenal Morphology
CT imaging was used to classify absence or presence of adrenal hy-
perplasia in adrenals with an abnormal morphology. The absence of 
hyperplasia group included adrenals with an adenoma, but without 
hyperplasia, the presence of hyperplasia group included adrenals with 
hyperplasia alone or hyperplasia and an adenoma. Hyperplasia was 
defined as mean limb width ≥5 mm.38 Patients with no adrenal abnor-
mality visible on CT images were excluded from the morphological 
analysis.
Statistical Analyses
Data were analyzed with the Kolmogorov-Smirnov and Shapiro-Wilk 
tests to determine distributions. Group differences were calculated for 
normally distributed data using the ANOVA and post hoc Bonferroni 
tests. Non-normally distributed data were analyzed using the Kruskal-
Wallis test. Accordingly, data are expressed as mean±SD or median 
(25th to 95th percentile). Categorical variables are presented as abso-
lute numbers, and percentages and differences were analyzed with a 
χ2test. Adjusted logistic regression analyses were performed to assess 
associations of AT1R-Abs and the diagnosis of BAH. IBM SPSS 
Statistics version 22.0 was used for all analyses.
Results
Clinical Parameters of Patients With PA Versus 
Primary Hypertension
Groups of patients with APA and BAH had the same age as 
patients with PH and a similar sex distribution with no sig-
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between APA, BAH, and PH groups (47.5%–57.9%). There 
were no significant between-group differences in systolic or 
diastolic blood pressure at baseline or in body mass index 
in patients with APA, BAH, and PH (Table 1). As expected, 
patients with APA or BAH had higher plasma aldosterone 
concentrations and lower direct plasma renin concentrations 
(DRC) at baseline relative to the PH group (plasma aldoste-
rone concentrations: APA group, 569 [283–1071]; BAH, 416 
[311–583]; PH 225 [128–394] pmol/L and DRC: APA group, 
4.3 [2.0–11.2]; BAH, 3.4 [2.0–7.3]; PH, 18.2 [8.9–45.1] 
mU/L). Likewise, patients with APA had lower serum potas-
sium concentrations compared with patients with BAH and 
PH (APA group, 2.9 [2.6–3.2]; BAH, 3.3 [3.0–3.7]; PH 3.9 
[3.6–4.2] mmol/L; Table 1).
ELISA Quantification of AT
1
R-Abs in Different 
Groups
Autoantibodies recognizing epitopes on the full-length human 
recombinant AT1R in serum from patients with APA, BAH, 
PH, preeclampsia, and NT were measured using 2 different 
ELISAs. Using one approach (ELISA-Creative Diagnostics), 
patients with preeclampsia displayed significantly higher 
AT1R-Ab levels compared with all other groups (P<0.0001 
for all comparisons). The titer of AT1R-Abs was highly sim-
ilar in the APA and BAH groups (APA group, [0.06–0.21]; 
BAH, 0.12 [0.06–0.26] ng/mL) with no differences observed 
compared with either the PH or NT groups (PH group, 0.15 
[0.10–0.25]; NT, 0.11 [0.01–0.19] ng/mL; Figure [A]; Table 
S1). We also used a second ELISA (ELISA-CellTrend) based 
on AT1R-Ab binding to the full-length AT1R in its native con-
formation.36,37 Patients with APA and BAH displayed highly 
similar levels of AT1R-Abs (APA group, 14.2 [10.4–22.0]; 
BAH, 14.1 [10.1–19.7] U/mL) which were not significantly 
different from the PH or NT groups (PH group, 13.5 [10.7–
18.7]; NT, 11.4 [10.6–20.8] ng/mL; Figure [B], Table S1). 
However, AT1R-Ab levels were significantly lower in patients 
with preeclampsia (8.7 [6.9–11.6] ng/mL) compared with all 
other groups (P<0.05 for all comparisons).
Quantification of AT1R Agonistic Activity in Serum 
Samples From Different Groups
We tested if serum from the different subgroups of patients 
and individuals could activate the AT1R in a cell-based func-
tional assay. Treatment of cells with angiotensin II (0–500 
pmol/L) demonstrated a dose-dependent effect on AT1R ac-
tivation which was ablated by preincubation of the cells for 
1 hour with the AT1R antagonist losartan (100 μmol/L). The 
assay measured a specific AT1R functional response to 50 
pmol/L angiotensin II which was significantly higher than a 
corresponding incubation in the presence of losartan (P<0.05; 
Figure S2). Higher AT1R agonistic activity was measured in 
serum samples from all groups (P<0.001 for absence versus 
presence of losartan for each group). There were no between-
group differences for AT1R agonist activity in the absence 
of losartan. However, in the presence of losartan there were 
overall differences in the measured functional activation of 
the AT1R (P<0.001) with the BAH group showing higher 
activity compared with the APA (P=0.001), preeclampsia 
(P<0.0001), and NT groups (P<0.0001). The PH group also 
displayed higher levels of functional AT1R-Abs relative to 
the NT (P<0.0001) and the preeclampsia groups (P=0.001; 
Figure [C], Table S1).
Affinity Isolation of IgG Fractions From Different 
Groups of Serum Samples
To determine if the losartan-independent AT1R activating ac-
tivity in serum samples was due to IgGs or to other circulating 
factors, such as angiotensin II, IgGs were affinity-isolated 
from all serum samples on protein A/G-agarose to assess 
AT1R agonist activity in the cell-based AT1R functional assay 
(Figure S1 and S2). We first tested if the IgG affinity isola-
tion procedure produced functionally active autoantibodies. 
For this, IgGs were isolated from the serum of patients with 
Graves disease (N=9) and measured TSHR activation using a 
cell-based functional assay. Using IgG fractions isolated from 
patients with Graves disease, comparison of TSHR activation 
in the ACT-ONE cell line (with stable overexpression of the 











APA vs BAH APA vs PH BAH vs PH
Age, y 52±10.2 52±9.7 52±19.9 0.964 N.A. N.A. N.A.
Sex, ref. male 21 (52.5%) 19 (47.5%) 16 (42.1%) 0.656 N.A. N.A. N.A.
BMI, Kg/m2 27.3±4.1 26.2±5.0 27.4±6.0 0.500 N.A. N.A. N.A.
Systolic BP, mm Hg 151±21.5 151±23.8 156±17.2 0.461 N.A. N.A. N.A.
Diastolic BP, mm Hg 93±11.0 95±13.6 91±14.6 0.469 N.A. N.A. N.A.
PAC, pmol/L 569 [283–1071] 416 [311–583] 225 [128–394] <0.001 0.742 <0.001 0.002
DRC, mU/L 4.3 [2.0–11.2] 3.4 [2.0–7.3] 18.2 [8.9–45.1] <0.001 0.831 <0.001 <0.001
ARR_DRC 108 [36–306] 114 [71–162] 16 [6–26] <0.001 1.000 <0.001 <0.001
Lowest serum K+, mmol/L 2.9 [2.6–3.2] 3.3 [3.0–3.7] 3.9 [3.6–4.2] <0.001 0.001 <0.001 <0.001
Clinical data of patients with PA (APA or BAH) and PH are presented as average values±SD, absolute numbers with proportions in parenthesis (%) or as medians 
with lower and upper quartiles in parentheses. P values designate the presence of group differences by the ANOVA and Bonferroni post hoc tests (age, BMI, systolic, 
and diastolic BP), Kruskal–Wallis test (PAC, DRC, ARR_DRC, and potassium), or χ2 test (sex). Numbers of patient samples in each subgroup are indicated. APA indicates 
aldosterone-producing adenoma; ARR_DRC, aldosterone-to-renin ratio using direct renin measurements; BAH, bilateral adrenal hyperplasia; BMI, body mass index; BP, 
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human TSHR) with the parental cell line (without expression 
of recombinant human TSHR) demonstrated that 6 of the 9 
IgG fractions displayed TSHR agonistic activity (Figure S3). 
The remaining 3 IgG fractions exhibited no significant TSHR 
activation indicating neutral or blocking activity to the TSHR 
(Figure S3). Overall, the approach used for the affinity iso-
lation of autoantibodies from patients with Graves disease 
maintained TSHR agonist functional activity, thereby validat-
ing the method used for the isolation of IgG fractions.
Quantification of AT1R Agonistic Activity in 
Affinity-Isolated IgG Fractions From Different 
Groups
There were group differences in the cell-based assay response 
(overall difference P<0.001) using affinity-isolated IgGs. The 
BAH, PH, and preeclampsia groups displayed higher levels of 
AT1R activating autoantibodies compared with the NT group 
(P<0.0001, P=0.007, and P<0.0001, respectively), and the 
BAH group had higher functional AT1R-Ab levels than the 
APA group (P=0.01). The agonistic AT1R-Ab levels were not 
abolished in the presence of losartan, and significant group dif-
ferences were observed (Table S1). Higher losartan-indepen-
dent AT1R functional activity was measured with IgGs isolated 
from patients with BAH, PH, and preeclampsia compared with 
the NT group (P<0.0001, P=0.006, and P=0.016, respectively) 
and in the BAH versus APA groups (P=0.01; Figure [D], Table 
S1). Comparison of AT1R activation in the cell assay with the 
functional response obtained with angiotensin II in the dose-
response assay indicated that the median AT1R activation 
achieved with affinity-isolated antibodies from patients with 
BAH in the presence or absence of losartan was equivalent to 
50 to 100 pmol/L angiotensin II (Figure S2 and Table S1).
Clinical Parameters of Patients According to 
Functional AT1R-Ab Levels
Affinity-purified agonistic AT1R-Ab levels were categorized 
into higher and lower AT1R-Ab levels according to the me-
dian AT1R-Ab activity in the cell-based assay for patients 
with APA, BAH, and PH combined. In this cohort, in the ab-
sence of losartan, patients with BAH had higher AT1R-Ab 
levels (BAH represented 41.2% of 68 patients of the com-
bined cohort with higher AT1R-Ab levels compared with 
23.1% of 52 patients with lower AT1R-Ab levels, P=0.037; 
Table 2). Patients with APA had lower AT1R-Ab levels (APA 
represented 23.5% of 68 patients of the combined cohort with 
higher AT1R-Ab levels compared with 46.2% of 52 patients 
Figure. Measurement of AT1R (angiotensin II type 1 receptor) autoantibodies and AT1R activating response in patients with primary aldosteronism, primary 
hypertension, preeclampsia, and in normotensive individuals. Scatter dot plots showing quantification of AT1R-Abs in total serum of patients with primary 
aldosteronism (PA; aldosterone-producing adenoma [APA] and bilateral adrenal hyperplasia [BAH]), primary hypertension (PH), preeclampsia (PE), and 
normotensive individuals by measurements using ELISA-Creative Diagnostics (A) or ELISA-CellTrend (B). A cell-based AT1R activation assay was used to 
measure AT1R-Ab agonist activity in total serum (C) or in agarose-A/G affinity-isolated IgG fractions (D) in the absence (light gray points) or presence (dark 
gray points) of 100 µm losartan as indicated. D, also highlights the agonistic AT1R-Ab levels in patients with adrenal hyperplasia at computed tomographic 
imaging (red points). The response ratio represents AT1R activation of β-lactamase activity measured as coumarin to fluorescein fluorescence (cleaved 
to uncleaved substrate ratio) normalized for negative controls. Horizontal lines within boxes indicate the median, and the lower and upper horizontal lines 
indicate the 95% CI. P values were calculated using the Kruskal-Wallis test and indicate **** difference (P<0.0001) from NT (A); *difference (P<0.05) from 
normotensive individuals (NT, B); ***difference (P<0.001) absence vs presence of losartan for each subgroup; $difference (P<0.01) from BAH; ####difference 
(P<0.0001) from NT (presence of losartan); ++++difference (P<0.0001) from PE (presence of losartan); ++difference (P<0.01) from PE (presence of losartan); 
(C); **difference (P<0.01) from NT (absence of losartan), ****difference (P<0.0001) from NT (absence of losartan); $difference (P<0.01; presence of losartan); 
####difference (P<0.0001) from NT (presence of losartan); ##difference (P<0.01) from NT (presence of losartan); #difference (P<0.05) from NT (presence of 
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with lower AT1R-Ab levels, P=0.009; Table 2). Although 
functional AT1R-Ab levels were similar in the BAH versus 
PH groups (Figure [D]; Table S1), patients with PH with lower 
versus higher AT1R-Ab levels were similarly distributed in 
the combined cohort (APA+BAH+PH). The PH group with 
lower AT1R-Ab levels comprised 30.7% of 52 patients of the 
combined cohort compared with 35.3% of 68 patients with 
higher levels (P=0.603; Table 2).
In the APA, BAH, and PH combined cohort, higher lev-
els of agonistic AT1R-Abs were also associated with a higher 
aldosterone-to-renin ratio (ARR_DRC) and a lower DRC in 
the absence of losartan (DRC: 5.7 mU/mL [2.2–27.0] versus 
11.7 mU/mL [5.7–31.8], P=0.011; ARR_DRC: 47 [13–139] 
versus 23 [10–55], P=0.029, for higher versus lower AT1R-Ab 
levels, respectively), and these differences were maintained in 
the presence of losartan (Table 2).
Patients with PA with higher agonistic AT1R-Ab levels, in 
the absence of losartan, had an increased likelihood of a diag-
nosis of BAH versus APA after adjustment for confounding 
effects of age, systolic BP, plasma aldosterone concentrations, 
or DRC (Table 3). Higher losartan-independent agonistic 
AT1R-Ab levels were not associated with a diagnosis of 
BAH compared with APA after correction for systolic BP and 
plasma aldosterone concentrations. There was no association 
of higher AT1R-Ab levels with a diagnosis of BAH compared 
with PH in either the absence of presence of losartan (Table 3).
Adrenal Morphology According to Functional 
AT1R-Ab Levels
Adrenal abnormalities were absent on CT images in 3 patients 
diagnosed with APA and in 17 patients diagnosed with BAH, 
and these cases were excluded from the morphological anal-
ysis. Higher affinity-purified AT1R-Ab levels in the absence 
of losartan were associated with the presence of adrenal hy-
perplasia, when AT1R-Ab levels were treated as either a con-
tinuous variable (AT1R activating activity response ratio, 0.3 
[0.26–0.39] versus 0.26 [0.23–0.29] in the presence and ab-
sence of hyperplasia, respectively, P=0.011) or categorized 
as higher or lower according to the median AT1R-Ab level 
(76.0 % of 25 patients with adrenal hyperplasia had higher 
AT1R-Ab levels compared with 37.1% of 35 patients without 
adrenal hyperplasia, P=0.003; Table 4). In the presence of 
losartan, AT1R-Ab activities were similar in the presence 
versus absence of hyperplasia groups (Table 4).
The distribution of individual patients with PA (APA and 
BAH) with adrenal hyperplasia according to AT1R-Ab acti-
vating activity is shown in Figure [D]. In patients with PA, 
83.3% of 12 and 69.2% of 13 patients of patients classified 
with adrenal hyperplasia in the APA and BAH groups, respec-
tively, had AT1R-Ab levels above or equal to the median value 
for their group in the absence of losartan (Figure [D]).
Discussion
Autoantibodies that potentially elicit a functional response by 
binding to G protein-coupled receptors have been described 
in several cardiovascular disorders.25 Many studies have re-
ported AT1R-Ab binding to an epitope in the second extra-
cellular loop (AFHYESQ) of the AT1R in different groups 
of patients.20 The best characterized is AT1R-Abs in pree-
clampsia where a functional role has been implicated using 
cardiomyocyte contraction assays in which assay response 
was ablated either by the AT1R antagonist losartan or with 
Table 2. Clinical Parameters of Patients With Primary Aldosteronism and Primary Hypertension According to Functional AT1R-Ab Levels
Clinical Parameter
AT1R-Ab Level Minus Losartan
P Value
AT1R-Ab Level Plus Losartan
P Value<Median ≥Median <Median ≥Median
Diagnosis
  APA 24 (46.2) 16 (23.5) 0.009 23 (40.4) 17 (27.0) 0.120
  BAH 12 (23.1) 28 (41.2) 0.037 14 (24.6) 26 (41.3) 0.053
  PH 16 (30.7) 24 (35.3) 0.603 20 (35.1) 20 (31.7) 0.699
Age, y 54±14.8 55±16.6 0.749 54±15.5 55±16.2 0.851
Sex, ref. male 30 (57.7) 39 (57.4) 0.970 28 (49.1) 41 (65.1) 0.077
BMI, Kg/m2 28.2±4.7 27.5±5.0 0.431 27.2±4.2 28.4±5.3 0.177
Systolic BP, mm Hg 151±23.9 147±19.2 0.376 148±25.1 149±17.4 0.709
Diastolic BP, mm Hg 92±15.0 86±12.5 0.018 89±16.9 89±10.7 0.854
PAC, pmol/L 235 [150–553] 300 [167–556] 0.499 236 [130–550] 286 [186–569] 0.338
DRC, mU/L 11.7 [5.7–31.8] 5.7 [2.2–27.0] 0.011 11.9 [5.3–39.7] 5.6 [2.3–16.3] 0.003
ARR_DRC 23 [10–55] 47 [13–139] 0.029 19 [7–60] 49 [16–137] 0.003
Lowest serum K+, mmol/L 3.2 [2.9–3.9] 3.4 [3.2–3.9] 0.333 3.3 [2.9–3.9] 3.4 [3.2–3.9] 0.084
Clinical parameters of the combined cohort of patients with APA, BAH, and PH were analyzed according to AT1R-Ab levels (affinity-purified autoantibody activity 
measured with the cell-based assay) categorized according to the median value of the combined cohort (median values, 0.27 and 0.28 in the absence and presence of 
losartan respectively). Data are presented as average values±SD, absolute numbers with proportions in parenthesis (%), or as medians with lower and upper quartiles 
in parentheses. P values designate the presence of group differences by the ANOVA and Bonferroni post hoc tests (age, BMI, systolic, and diastolic BP), Kruskal–Wallis 
test (PAC, DRC, ARR_DRC, and potassium), or χ2 test (sex, diagnosis). Numbers of patient samples in each subgroup are indicated. APA indicates aldosterone-producing 
adenoma; ARR_DRC, aldosterone-to-renin ratio using direct renin measurements; BAH, bilateral adrenal hyperplasia; BMI, body mass index; BP, blood pressure; DRC, 
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the AFHYESQ peptide.20,39 The prevalence of AT1R-Abs in 
preeclampsia varies widely with reports employing an ELISA 
ranging from 48% of 58 patients40 to 100% of 25 patients.20 
However, targeting the AFHYESQ peptide in ELISA assays 
has limitations because binding to linear immobilized peptides 
may not correlate with AT1R agonism and binding to confor-
mational epitopes cannot be assessed.41 A commercially avail-
able ELISA (ELISA-CellTrend), routinely used in solid organ 
transplantation, has been developed based on autoantibody 
binding to the full-length AT1R in the native conformation.37 
Using this conformation sensitive assay, we demonstrated 
highly contrasting low AT1R-Ab levels compared with a dif-
ferent ELISA method which appears to greatly overestimate 
the level of AT1R-Abs in patients with preeclampsia.
The pathophysiology of sporadic BAH is poorly under-
stood. Advances in knowledge are hampered by the highly 
limited availability of tissue samples for molecular studies be-
cause patients with BAH are not usually surgically treated. 
Despite this, recent studies have suggested a role for adre-
nocortical hyperplasia in patients with bilateral but asym-
metrical inappropriate aldosterone production42 or a role for 
small clusters of cells located beneath the adrenal capsule with 
high aldosterone synthase expression (called aldosterone-pro-
ducing cell clusters) in surgically treated patients diagnosed 
with bilateral PA.43 Thus, BAH may not be a distinct entity 
but a disorder comprising clinical and biochemical variability 
arising from morphological heterogeneity representing the 
variable response of the adrenal cortex to circulating, environ-
mental, and genetic factors.
A role for autoantibodies that trigger bilateral chronic 
stimulation of the adrenal zona glomerulosa via activation of 
the AT1R has been proposed,44 but a pathogenic role for AT1R-
Abs in PA remains unclear because of conflicting reports that 
used different methods for assessment of antibody levels.28–30 
One study found a 2-fold increase of AT1R-Abs against the 
AFHYESQ peptide in an ELISA in patients with APA (n=26) 
compared with patients with BAH (n=20) and proposed the 
use of this assay as a potential diagnostic tool to differentiate 
the 2 different types of PA.28 Using a similar ELISA-based 
AFHYESQ assay, no difference in AT1R-Ab levels were 
observed in 44 patients with PA (15 with APA and 29 with 
BAH) compared with 18 normotensive individuals (n=18) and 
no difference in AT1R-Ab levels between the patients with 
APA and BAH.30 However, measuring antibody binding to the 
linear AFHYESQ peptide in ELISA assays, as used in many 
studies, does not necessarily correlate with AT1R agonism.
To address the agonistic activity of AT1R-Abs in PA, 
Kem et al29 reported increased AT1R-Ab levels in patients 
Table 3. Association of Agonistic Affinity-Purified AT1R-Ab Levels and Diagnosis of BAH
Clinical Parameter
BAH vs APA BAH vs PH
OR (CI 95%) P Value OR (CI 95%) P Value
Agonistic AT1R-Ab level−losartan
  AT1R-Abs, ref. ≥median 3.425 (1.342–8.696) 0.010 1.515 (0.589–3.891) 0.388
  Age, y 0.976 (0.941–1.012) 0.186 1.025 (0.997–1.053) 0.078
  AT1R-Abs, ref. ≥median 3.663 (1.420–9.434) 0.007 1.495 (0.587–8.817) 0.339
  Systolic BP, mm Hg 1.019 (0.005–1.044) 0.116 0.993 (0.972–1.015) 0.532
  AT1R-Abs, ref. ≥median 3.521 (1.361–9.091) 0.009 1.887 (0.688–5.319) 0.231
  PAC, pmol/L 1.001 (1.000–1.003) 0.072 1.003 (1.001–1.005) 0.003
  AT1R-Abs, ref. ≥median 3.546 (1.395–9.009) 0.008 1.603 (0.630–4.065) 0.322
  DRC, mU/L 0.996 (0.989–1.004) 0.298 0.996 (0.990–1.002) 0.221
Agonistic AT1R-Ab Level+Losartan
  AT1R-Abs, ref. ≥median 2.571 (1.027–6.452) 0.044 1.980 (0.786–5.000) 0.147
  Age, y 0.973 (0.938–1.009) 0.135 1.026 (0.999–1.055) 0.062
  AT1R-Abs, ref. ≥median 2.358 (0.943–5.882) 0.066 1.832 (0.745–4.505) 0.187
  Systolic BP, mm Hg 1.015 (0.992–1.039) 0.211 0.993 (0.971–1.014) 0.497
  AT1R-Abs, ref. ≥median 2.381 (0.947–5.988) 0.065 2.278 (0.838–6.211) 0.107
  PAC, pmol/L 1.001 (1.000–1.002) 0.086 1.003 (1.001–1.005) 0.003
  AT1R activation, ref. ≥median 2.500 (1.007–6.211) 0.048 1.698 (0.678–4.255) 0.258
  DRC, mU/L 0.966 (0.989–1.004) 0.323 0.997 (0.990–1.003) 0.314
Logistic regression analyses were performed to determine the potential association of agonistic autoantibody levels with 
a diagnosis of BAH with adjustment for confounding effects of a single clinical variable per level (age, systolic BP, PAC, or 
DRC) in the absence and presence of losartan. Autoantibody levels were categorized according to the median affinity-purified 
AT1R-Ab level in the cell-based assay as shown. Data are presented as OR with 95% CI. An OR >1 indicates an increased 
likelihood for a diagnosis of BAH in the presence of agonistic AT1R-Ab activity ≥ median value independent of the tested 
confounding variable (age, systolic BP, PAC, and DRC). APA indicates aldosterone-producing adenoma; AT1R, angiotensin II 
type 1 receptor; BAH, bilateral adrenal hyperplasia; BP, blood pressure; DRC, direct renin concentration; OR, odds ratio; PAC, 
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with PA (n=13) compared with control subjects (n=20) using 
cell-based assays to measure a functional response in AT1R-
transfected cells and reported the contractile effects of the 
isolated IgGs in perfused rat cremaster arterioles. In con-
trast to other reports, an increased prevalence of AT1R-Abs 
in patients with BAH relative to patients with APA was re-
ported.29 However, the number of patients with PA assessed 
for AT1R-Ab levels was small, the stimulating activity of low 
potency and the affinity-isolated antibodies did not elicit a 
dose-dependent functional effect.29
The diverse observations for the prevalence and poten-
tial role of AT1R-Abs and the limited understanding of the 
pathogenesis of bilateral PA highlight the need for studies 
to measure autoantibodies using robust functional assays 
in large and well-characterized cohorts of patients with 
PA. Herein, we assessed AT1R-Ab levels in a cohort of 80 
patients with PA diagnosed in accordance with rigorous crite-
ria and with subtype diagnosis (APA versus BAH) defined by 
adrenal venous sampling. After this approach, ELISA-based 
measurements using the immobilized full-length AT1R gave 
contrasting results for AT1R-Ab levels in patients with pre-
eclampsia and did not reveal statistical differences between 
patients with BAH or APA compared with PH or NT. We, 
hence, also used a cell-based AT1R functional assay which 
exploits specific activation of the β-lactamase reporter gene 
on ligand binding to the AT1R. With this assay, similar lev-
els of AT1R activation were measured in whole serum from 
all groups. However, between-group differences were shown 
using affinity-isolated IgGs which demonstrated significantly 
higher levels of agonistic AT1R-Abs in patients with BAH 
compared with APA and in patients with BAH, PH, and pre-
eclampsia relative to the NT group both in the presence and 
absence of losartan.
These activities implicate the existence of an alterna-
tive epitope structurally remote from losartan binding sites. 
AT1R is increasingly recognized as a multi-ligand binding 
surface and epitopes discovered in solid organ transplant 
patients are not identical with those in patients with pree-
clampsia.37 Some reports suggest that, in addition to classical 
G protein-mediated signaling, biased AT1R signaling medi-
ated by β-arrestin45,46 may play a role in aldosterone produc-
tion and have pathological implications for the progression 
to heart failure after myocardial infarction.47,48 Because 
losartan antagonizes G protein signaling but is ineffective 
in ablating β-arrestin-mediated signaling,47,48 the losartan-
independent activity we report presumably comprises biased 
AT1R signaling.
We also demonstrate that higher agonistic AT1R-Ab levels 
are associated with clinical parameters characteristic of auton-
omous aldosterone production in PA, such as higher aldoste-
rone-to-renin ratios and lower plasma renin levels. The degree 
of functional activity of AT1R-Abs in this study appears low 
but is potentially pathologically relevant because the median 
AT1R-Ab agonistic activity in patients with BAH corresponds 
to greater than that achieved with 50 pmol/L angiotensin II, a 
concentration similar to plasma angiotensin II concentrations 
reported in patients with chronic kidney disease and consider-
ably higher than in healthy individuals.49
A potential pathogenic role of agonistic AT1R-Abs in PA 
is suggested by the association of higher active AT1R-Ab 
levels—in the absence but not in the presence of losartan—
with an increased likelihood of a diagnosis of BAH com-
pared with APA and with an increased incidence of adrenal 
hyperplasia. Adrenals harboring an APA also often display 
hyperplasia of the zona glomerulosa adjacent to the ade-
noma.42,50 It is notable that within the group of patients with 
APA, those with evidence of hyperplasia at CT scanning 
tend to display higher levels of AT1R-Ab agonistic activity 
compared with patients with APA without hyperplasia. The 
imaging data should, however, be treated with caution con-
sidering the potential for incorrect classification of an ade-
noma versus hyperplasia.
Taken together the present data indicate that AT1R-Abs 
may play a role in patients with BAH which could feasibly ex-
acerbate the effects of additional pathophysiological factors, 
such as aldosterone-producing cell clusters which have been 
reported as larger, more numerous and with a higher preva-
lence of aldosterone-driver mutations than normal adrenals.43 
Notwithstanding the observations reported herein, the possi-
bility that AT1R-Abs are a marker of hypertension rather than 
having a pathogenic role cannot be excluded.
In conclusion, some patients with disorders related to hy-
pertension have activating autoantibodies to the AT1R. Some 
AT1R-Abs function via a mechanism diverse from the classi-
cal G protein-mediated AT1R signaling and implicate a role 
for losartan-independent biased AT1R signaling. Overall, the 
present study suggests a role for agonistic autoantibodies to 
the AT1R in a subgroup of patients with PA, comprising those 
patients with adrenal hyperplasia.




ValueAbsence (n=35) Presence (n=25)
Diagnosis 0.066
  APA 25 (71.4) 12 (48.0)
  BAH 10 (28.6) 13 (52.0)
Agonistic AT1R-Ab level−losartan
  AT1R-Abs (response ratio) 0.26 [0.23–0.29] 0.30 [0.26–0.39] 0.011
  AT1R-Abs (ref. ≥median) 13 (37.1) 19 (76.0) 0.003
Agonistic AT1R-Ab level+losartan
  AT1R-Abs (response ratio) 0.27 [0.20–0.30] 0.30 [0.24–0.36] 0.149
  AT1R-Abs (ref. ≥median) 16 (45.7) 15 (60.0) 0.205
Adrenal morphology of patients with PA was determined from CT results to 
classify absence or presence of hyperplasia in adrenals with morphological 
abnormalities. Numbers of patient samples in each subgroup are indicated. 
Affinity-purified agonistic AT1R-Ab levels, measured with the cell-based assay, 
were treated as continuous variables and presented as medians with lower 
and upper quartiles in parenthesis or categorized as higher and lower agonistic 
AT1R-Ab levels according to the median value for patients with APA and BAH 
combined and presented as absolute numbers with proportions in parenthesis. 
P values designate the presence of group differences by the Kruskal–Wallis test 
(AT1R-Ab levels), or χ2 test (diagnosis, AT1R-Ab levels after categorization). APA 
indicates aldosterone-producing adenoma; AT1R, angiotensin II type 1 receptor; 
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Perspectives
A role for AT1R-Abs has been implicated in several cardio-
vascular disorders, but evidence for a direct function in di-
sease pathophysiology is lacking. In vivo, experiments in 
mice subjected to infusion of AT1R-Abs from patients with 
PA could clarify the impact of AT1R-Abs on aldosterone pro-
duction. A longitudinal analysis is planned to measure the 
response of AT1R-Ab levels to adrenal surgery or mineralo-
corticoid receptor antagonism in patients with PA with long-
term follow-up. Epitope mapping using synthetic peptides to 
competitively abolish autoantibody-mediated AT1R activation 
will aid the identification of AT1R-Ab binding sites and estab-
lish any role for autoantibodies in biased signaling.
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What Is New?
•	AT1R-Ab (autoantibodies to the angiotensin II type 1 receptor) levels 
were measured in groups of patients with hypertension compared with 
normotensive individuals.
•	Higher agonistic AT1R-Abs levels were present in bilateral primary al-
dosteronism, primary hypertension, and preeclampsia groups compared 
with normotensive individuals.
•	Patients with bilateral versus unilateral primary aldosteronism had higher 
levels of agonistic AT1R-Abs.
What Is Relevant?
•	AT1R-Abs measured by ELISA did not correlate with functional activation 
of the AT1R.
•	Patients with higher AT1R-Ab activity levels have an increased likelihood 
of a diagnosis of bilateral than unilateral primary aldosteronism.
•	Higher levels of agonistic AT1R-Abs were associated with higher aldo-
sterone-to-renin ratios and lower plasma renin concentrations.
•	Patients with primary aldosteronism with adrenal hyperplasia displayed 
higher agonistic AT1R-Abs levels.
Summary
Agonistic autoantibodies to the AT1R are present in patients with 
disorders related to hypertension and may contribute to autono-
mous aldosterone production and adrenal hyperplasia in a sub-
group of patients with primary aldosteronism.
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